Research article · 2021
Conference proceedingPublished 29 Oct 2022
Immune-Mediated Colitis with Concurrent Clostridium Difficile Infection
1Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia; 2Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia; 3Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia; 4Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia; 5Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia; 6Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia; 7Professor, Moscow Health Department, Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Immune checkpoint inhibitors (ICIs) are widely used for patients with primary lung cancer in the recent years and have better overall survival versus previously used chemotherapy [1]. Some adverse events of immunotherapy, such as diarrhea and colitis, can lead to treatment discontinuation due to the risk of fatal outcome. We present the case of pembrolizumab-induced colitis with concurrent clostridium difficile infection (CDI) in a patient with metastatic non-small cell lung cancer (NSCLC) [2,3]. 58-year-old man was hospitalized due to the symptoms of persisting watery diarrhea and diffuse abdominal pain. Laboratory tests on the day of admission were significant for mild iron deficiency anemia, hypoalbuminemia, hypoproteinemia, leukocytosis, and increased C-reactive protein (68,94 mg/ L) [4]. His stool polymerase chain reaction (PCR) test was positive for Clostridium diffcile A and B toxins [5,6]. The treatment for CDI had started with intravenous metronidazole (500 mg every 8 hours) and intravenous vancomycin (1000 mg every 12 hours). Flexible sigmoidoscopy detected edema, erythema, fibrine-covered erosions, loss of vascular pattern in sigmoid colon and rectum. Histological evaluation of the biopsy revealed increased lamina propria cellularity, glandular apoptotic changes, crypt abscesses, shortening, mucin cells depletion and increased number of intraepithelial lymphocyte (Figure 1). Most of them were CD3(+) cytotoxic T-lymphocytes (Figure 2). However, his symptoms failed to improve with antibiotics management. Due to the ongoing treatment with pembrolizumab and the lack of response to the severe CDI antibiotic treatment, the diagnosis of an IMC was made. After excluding an infection with cytomegalovirus, EBV by PCR in colonic tissue, an immunosuppression with intravenous prednisolone 120 mg daily was initiated. His diarrhea began to improve, abdominal pain resolved, and CRP levels decreased in six days. All patients receiving ICIs with diarrhea and infection should be suspected of immune-mediated colitis (IMS).
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 30 Jul 2017
Fe3-δO4 nanoparticles inspired clinical therapeutics in cancer and Clostridium difficile infection
Review article · 6 Aug 2017
The psychoneuroimmunotherapy of human immune-mediated systemic diseases, including cancer and autoimmune diseases
Conference abstract · 31 Jul 2017
SYN-004 (ribaxamase), an orally administered β-lactamase for prevention of antibiotic-mediated dysbiosis of the gut microbiome and Clostridium difficile infection in patients receiving intravenous β-lactam antibiot
Conference abstract · 2018
The characteristics of highly immunoreactive surface proteins of Clostridium difficile using human sera
More from this journal
The newest in Cervical Cancer: Open Access.
Perspective · 26 Nov 2025
Modern Cervical Screening: Progress, Equity, Future Strategies
Opinion · 26 Nov 2025
Evolving Cervical Cancer Screening: HPV, Tech, Equity
Perspective · 26 Nov 2025
HPV Vaccines: Proven Efficacy, Safety, Global Impact
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCervical Cancer: Open Access
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Saria Dbar”
- BylineArticles whose byline prints “Sariya Alekperzade”
- BylineArticles whose byline prints “Elena Sabelnikova”
- BylineArticles whose byline prints “Olga Akhmadullina”
- BylineArticles whose byline prints “Svetlana Bykova”
- BylineArticles whose byline prints “Filonenko Darya”
- BylineArticles whose byline prints “Asfold Parfenov”
